A phase III trial conducted by the Cytokine Working Group studied one course of bolus high-dose IL-2 vs. observation in high-risk ccRCC patients (T3b-c, T4, N1–3, or M1 disease resected to no evidence of disease) after CRN. The gene discussed is IL2; the disease is nonpapillary renal cell carcinoma.